Study, year, (study name) | Location | Duration of treatment (follow-up schedule) | Population | Interventions (Number of patients randomized, n) | Outcomes | % of randomized participants excluded from main analyses | Compliance to treatments. Mean percentage of study pills taken % (SD) | Summary of results |
---|---|---|---|---|---|---|---|---|
Baron 2003 (Aspirin/Folate Polyp Prevention Study (AFPPS)) [12] | United States | ≈3 years (3 years after the baseline examination) | Age - range, 21–81 years; % male: 64; subjects with history of adenomas; and documented clean colon post-polypectomy | Aspirin 81 mg/day (n = 169); aspirin 325 mg/day (n = 167); aspirin 81 mg/day and folic acid 1 mg/day (n = 175); aspirin 325 mg/day and folic acid 1 mg/day (n = 171); folic acid 1 mg/day (n = 170); placebo (n = 169). | Primary outcome: recurrent colorectal adenomas Secondary outcomes: numbers of colorectal adenomas and advanced adenomas (defined as those with tubule-villous adenomas (25 to 75% villous features), villous adenomas (more than 75% villous), large adenomas (at least 1 cm in diameter), severe dysplasia, or invasive cancer) | 3% excluded from analysis as no follow-up colonoscopy | Aspirin any dose- 91.7 (18.8); aspirin 81 mg- 91.9 (18.8); aspirin 325 mg- 91.6 (18.7); placebo- 90.3 (20.5) | Unadjusted relative Risk (95% CI): Aspirin any dose versus placebo Any adenoma: 0.88 (0.77–1.02) Advanced adenoma: 0.71 (0.50–1.00) Aspirin 81 mg versus placebo Any adenoma: 0.81 (0.69–0.96) Advanced adenoma: 0.59 (0.38–0.92) Aspirin 325 mg versus placebo Any adenoma: 0.96 (0.81–1.13) Advanced adenoma: 0.83 (0.55–1.23) |
Sandler 2003 (The colorectal adenoma preventions study [Cancer and Leukemia Group B (CALGB) 9270] [15] | United States | ≈3 years (Participants with early-stage disease at 4 years and all other participants at 3 years after the baseline examination) | Ages – range, 30–80 years; % male: 52; subjects with of histologically documented colon or rectal cancer with a low risk of recurrent disease; and documented clean colon post-polypectomy | Aspirin 325 mg/day (n = 317); placebo (n = 318) | Primary outcome: incidence of adenoma. Secondary outcomes: the size of the largest adenoma; the time to the detection of a first adenoma, and the proportion of patients with advanced adenomas (defined as those that were at least 1 cm in diameter or had villous components) | 19% excluded from analysis as no follow-up colonoscopy | Aspirin- 79.4 (26.8); placebo- 74.9 (28.5) | Adjusted relative risk (95% CI) Aspirin 325 mg versus placebo Any adenoma: 0.65 (0.46–0.91) Advanced adenoma: Not reported in the study. Risk ratio reported by Cole et al. [8] -0.77 (0.29–2.05) |
Logan 2008, (United Kingdom Colorectal Adenoma Prevention (ukCAP) trial) [14] | United Kingdom and Denmark | 3 years (3 years after the baseline examination) | Age – mean,58 years; range, 28–75 years; % male: 56; subjects with history of colorectal adenoma 0.5 cm or greater; and documented clean colon post-polypectomy | Aspirin 300 mg/day (n = 236); folic acid 0.5 mg/day (n = 234); aspirin 300 mg/day and folic acid 0.5 mg/day (n = 236); placebo (n = 233) | Primary outcome: recurrent colorectal adenomas Secondary outcomes: number of adenomas detected and incidence of advanced colorectal neoplasia (advanced colorectal neoplasia defined as adenomas that were either 1 cm or larger in diameter, villous or tubule-villous, or showed severe dysplasia or invasive cancer) | 10% excluded from analysis as no follow-up colonoscopy | Aspirin- 77.1 (35.2); placebo- 80.9 (31.6) | Relative Risk (95% CI) - Aspirin 300 mg versus placebo Any adenoma: 0.79 (0.63–0.99) Advanced adenoma: 0.63 (0.43–0.91) |
Benamouzig 2012 (Association pour la Prevention par l’ Aspirine du Cancer Colorectal (APACC) Study-4 year results) [17] | France | 4 years (4 years after the baseline examination) | Age – range, 18–75 years; % male: 70; subjects with history of at least 3 adenomas irrespective of size, or at least one measuring 6 mm in diameter or more; and documented clean colon post-polypectomy | Aspirin 160 mg/day (n = 73); aspirin 300 mg/day (n = 67); placebo (n = 132) (Aspirin ≈ lysine acetylsalicylate) | Primary outcomes: recurrent colorectal adenomas, and the adenomatous polyp burden Secondary outcomes: mean numbers of recurrent adenomas and numbers of recurrent advanced adenomas (defined as those with a maximum diameter of at least 10 mm, at least 25% villous elements or evidence of high-grade dysplasia) | 32% excluded from analysis as no follow-up colonoscopy at year 4 | Aspirin – 88 (26); placebo- 88 (26) | Aspirin any dose versus placebo (Relative risk, not reported) Any adenoma: Aspirin at any dose-42/102 (41%); Aspirin 160 mg-15/55 (27%); Aspirin 300 mg – 27/47 (57%); Placebo-33/83 (40%); non-significant. Advanced adenoma: Aspirin at any dose-10/182 (10%); Aspirin 160 mg-6/55 (11%); Aspirin 300 mg – 4/47 (8.5%); Placebo-7/83 (7%); non-significant. |
Ishikawa 2014 [16] | Japan | 2 years (2 years after the baseline examination) | Age - range, 40–70 years; % male: 79; subjects with history of colorectal adenomas and/or adenocarcinomas with invasions confined to the mucosa; and documented clean colon post-polypectomy | Aspirin (enteric-coated) 100 mg/day (n = 191); placebo (n = 198). | Primary outcome: incidence of adenoma or adenocarcinoma recurrence (advanced adenomas defined as high-grade dysplasias) Secondary outcomes: recurring tumor number, size and histology as well as the effects of lifestyle, such as smoking and alcohol drinking, and the frequency of adverse effects | not available (Stated “no significant difference between the two groups in compliance rates”) | Adjusted odds ratio (OR) Aspirin 100 mg versus placebo Any adenoma (reported as colorectal tumour): 0.60 (95% CI 0.36 to 0.98) Advanced adenoma: Adjusted OR not reported. [Reported incidence of high grade dysplasia: Aspirin-1/152 (0.7%); Placebo-2/159 (1.3%)] |